Last reviewed · How we verify

Pharmacological stress agents

GE Healthcare · Phase 3 active Small molecule

Pharmacological stress agents is a Cardiac stress agents Small molecule drug developed by GE Healthcare. It is currently in Phase 3 development for Diagnostic imaging agent for assessment of myocardial perfusion and coronary artery disease, Evaluation of cardiac function in patients unable to perform exercise stress testing.

Pharmacological stress agents induce controlled cardiac stress through vasodilation or increased heart rate to assess myocardial perfusion and function during diagnostic imaging.

Pharmacological stress agents induce controlled cardiac stress through vasodilation or increased heart rate to assess myocardial perfusion and function during diagnostic imaging. Used for Diagnostic imaging agent for assessment of myocardial perfusion and coronary artery disease, Evaluation of cardiac function in patients unable to perform exercise stress testing.

At a glance

Generic namePharmacological stress agents
SponsorGE Healthcare
Drug classCardiac stress agents
TargetAdenosine A2A receptor (adenosine); dopamine and beta-adrenergic receptors (dobutamine); adenosine A2A receptor (regadenoson)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

These agents (commonly adenosine, regadenoson, or dobutamine) simulate the hemodynamic effects of exercise stress without physical exertion, allowing visualization of coronary blood flow reserve and detection of ischemia. They are used in nuclear cardiology and echocardiography to evaluate patients who cannot undergo exercise stress testing, revealing areas of reduced perfusion that indicate coronary artery disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pharmacological stress agents

What is Pharmacological stress agents?

Pharmacological stress agents is a Cardiac stress agents drug developed by GE Healthcare, indicated for Diagnostic imaging agent for assessment of myocardial perfusion and coronary artery disease, Evaluation of cardiac function in patients unable to perform exercise stress testing.

How does Pharmacological stress agents work?

Pharmacological stress agents induce controlled cardiac stress through vasodilation or increased heart rate to assess myocardial perfusion and function during diagnostic imaging.

What is Pharmacological stress agents used for?

Pharmacological stress agents is indicated for Diagnostic imaging agent for assessment of myocardial perfusion and coronary artery disease, Evaluation of cardiac function in patients unable to perform exercise stress testing.

Who makes Pharmacological stress agents?

Pharmacological stress agents is developed by GE Healthcare (see full GE Healthcare pipeline at /company/ge-healthcare).

What drug class is Pharmacological stress agents in?

Pharmacological stress agents belongs to the Cardiac stress agents class. See all Cardiac stress agents drugs at /class/cardiac-stress-agents.

What development phase is Pharmacological stress agents in?

Pharmacological stress agents is in Phase 3.

What are the side effects of Pharmacological stress agents?

Common side effects of Pharmacological stress agents include Chest discomfort or angina, Dyspnea, Headache, Flushing, Palpitations, Hypotension.

What does Pharmacological stress agents target?

Pharmacological stress agents targets Adenosine A2A receptor (adenosine); dopamine and beta-adrenergic receptors (dobutamine); adenosine A2A receptor (regadenoson) and is a Cardiac stress agents.

Related